FR2068477A1 - - Google Patents

Info

Publication number
FR2068477A1
FR2068477A1 FR7029224A FR7029224A FR2068477A1 FR 2068477 A1 FR2068477 A1 FR 2068477A1 FR 7029224 A FR7029224 A FR 7029224A FR 7029224 A FR7029224 A FR 7029224A FR 2068477 A1 FR2068477 A1 FR 2068477A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7029224A
Other languages
French (fr)
Other versions
FR2068477B1 (nl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of FR2068477A1 publication Critical patent/FR2068477A1/fr
Application granted granted Critical
Publication of FR2068477B1 publication Critical patent/FR2068477B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7029224A 1969-08-08 1970-08-07 Expired FR2068477B1 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84873969A 1969-08-08 1969-08-08

Publications (2)

Publication Number Publication Date
FR2068477A1 true FR2068477A1 (nl) 1971-08-27
FR2068477B1 FR2068477B1 (nl) 1974-03-22

Family

ID=25304142

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7029224A Expired FR2068477B1 (nl) 1969-08-08 1970-08-07

Country Status (6)

Country Link
BE (1) BE754587A (nl)
BR (1) BR6915179D0 (nl)
DE (1) DE2034640C3 (nl)
FR (1) FR2068477B1 (nl)
GB (1) GB1268469A (nl)
NL (1) NL166018C (nl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2228482A1 (nl) * 1973-05-11 1974-12-06 Roussel Uclaf

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416872A (en) * 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
ZA743269B (en) * 1973-06-15 1975-05-28 Upjohn Co Anti-hypertensive compounds
PH22302A (en) * 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
KR100238346B1 (ko) * 1993-04-07 2000-03-02 오쓰까 아끼히꼬 피페리딘 유도체를 유효성분으로 하는 말초혈관확장제
MY142362A (en) 2004-01-29 2010-11-30 Otsuka Pharma Co Ltd Pharmaceutical composition for promoting angiogenesis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6909232A (nl) * 1968-11-08 1970-05-12

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6909232A (nl) * 1968-11-08 1970-05-12

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2228482A1 (nl) * 1973-05-11 1974-12-06 Roussel Uclaf

Also Published As

Publication number Publication date
NL7010668A (nl) 1971-02-10
FR2068477B1 (nl) 1974-03-22
DE2034640C3 (de) 1980-06-12
BE754587A (fr) 1971-02-08
GB1268469A (en) 1972-03-29
NL166018C (nl) 1981-06-15
NL166018B (nl) 1981-01-15
DE2034640A1 (de) 1971-02-11
DE2034640B2 (nl) 1979-09-27
BR6915179D0 (pt) 1973-02-13

Similar Documents

Publication Publication Date Title
AU465452B2 (nl)
AU429630B2 (nl)
AU450150B2 (nl)
AU2355770A (nl)
AU442375B2 (nl)
AU470301B1 (nl)
AU427401B2 (nl)
AU442538B2 (nl)
AU442554B2 (nl)
AU410358B2 (nl)
AU470661B1 (nl)
AU414607B2 (nl)
AU417208B2 (nl)
AU438128B2 (nl)
AU428131B2 (nl)
AU442285B2 (nl)
AU442322B2 (nl)
AU442357B2 (nl)
AU428129B2 (nl)
AU442380B2 (nl)
AU442463B2 (nl)
AU428074B2 (nl)
AU5228269A (nl)
AU5133369A (nl)
AU4949169A (nl)

Legal Events

Date Code Title Description
ST Notification of lapse